Outcomes and Trends of Prostate Biopsy for Prostate Cancer in Chinese Men from 2003 to 2011

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Na, Rong ^a,b   Jiang, Haowen ^a   Kim, Seong Tae ^b   Wu, Yishuo ^a   Tong, Shijun ^a   Zhang, Limin ^a   Xu, Jianfeng ^a,b   Sun, Yinghao ^c   Ding, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHINA; CHINESE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; ONSET AGE; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TISSUE LEVEL; TRANSRECTAL ULTRASONOGRAPHY; TREND STUDY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CHINA; HUMANS; MALE; NEOPLASM GRADING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84870051018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049914     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, et al. (2010) The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res 16: 4374-4381.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
4. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, et al. (2008) Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101: 809-816.
5. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, et al. (2002) Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 325: 766-770.
6. Zaytoun OM, Kattan MW, Moussa AS, Li J, Yu C, et al. (2011) Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information. Urology 78: 392-398.
7. Schwartz MJ, Hwang DH, Hung AJ, Han J, McClain JW, et al. (2008) Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy. Cancer 112: 1718-1725.
8. Zhu G, Lu ZH, Ma H, Yan W, Wan B, et al. (2009) [Ultrasound guided transrectal prostate biopsy: 11-year experience]. Zhonghua Yi Xue Za Zhi 89: 955-957.
9. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, et al. (1999) Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017-1024.
10. Schwartz KL, Grignon DJ, Sakr WA, Wood DP Jr, (1999) Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996. Urology 53: 769-774.
11. Catalona WJ, (1993) Treatment strategies for prostate cancer. JAMA 270: 1691; author reply 1693.
12. Keetch DW, Catalona WJ, Smith DS, (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571-1574.
13. Eskew LA, Bare RL, McCullough DL, (1997) Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157: 199-202; discussion 202-193.
14. Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW, (1998) Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 52: 808-813.
15. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, et al. (2000) A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163: 152-157.
16. Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, et al. (2000) Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 164: 393-396.
17. Chan TY, Chan DY, Stutzman KL, Epstein JI, (2001) Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 166: 2181-2184.
18. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, et al. (2001) Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 165: 1554-1559.
19. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ, (2000) A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 164: 388-392.
20. Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF, (2003) The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol 169: 130-135.
21. Kim JW, Lee HY, Hong SJ, Chung BH, (2004) Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J 45: 671-675.
22. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level
23. Dong F, Wang C, Farris AB, Wu S, Lee H, et al. (2012) Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol 36: 838-843.
24. Billis A, Guimaraes MS, Freitas LL, Meirelles L, Magna LA, et al. (2008) The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 180: 548-552; discussion 552-543.
25. Zareba P, Zhang J, Yilmaz A, Trpkov K, (2009) The impact of the 2005 International Society of Urological Pathology (ISUP) consensus on Gleason grading in contemporary practice. Histopathology 55: 384-391.
26. Egevad L, Mazzucchelli R, Montironi R, (2012) Implications of the International Society of Urological Pathology modified Gleason grading system. Arch Pathol Lab Med 136: 426-434.
27. Delahunt B, Miller RJ, Srigley JR, Evans AJ, Samaratunga H, (2012) Gleason grading: past, present and future. Histopathology 60: 75-86.